Green Innovation's animal additive bid is off the table
The FDA withdrew Green Innovation GmbH's animal-use additive petition, leaving no new approved use from that petition to reach farms, grocery shelves or
By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

Key points
- FDA’s September 10, 2026 Federal Register notice says Green Innovation GmbH withdrew its animal-use food additive petition.
- The withdrawal did not create a new FDA-authorized use from this petition for farms raising food animals.
- The supplied record names no ingredient, species, dollar amount, lobbying disclosure, product, label change or grocery-price effect.
- FDA is the decider in this record, and no next comment deadline or decision date is stated in the notice.
- A future FDA filing or authorization is the next concrete milestone that could show a food-chain effect.
A grocery cart does not change just because a company asks for a new animal-production additive. It changes only if the additive clears the federal gate that determines what farms may legally use in animals that enter the food supply. On Sept. 10, 2026, that gate closed for Green Innovation GmbH's pending request when the Food and Drug Administration published a notice in the Federal Register withdrawing the company's food additive petition for animal use.
The documented supply chain runs from farms and harvests to grocery shelves, restaurant kitchens, factory input costs, public health guidelines and daily diets. What a farm can raise and sell shapes what ends up on dinner tables. This regulatory filing touches the animal-production link in that chain. Yet it does not establish any immediate change to the meat, milk, eggs, produce, grocery prices, restaurant menus, labels or diets that consumers see today. The petition stopped here FDA closed the pending route
In its Sept. 10 Federal Register notice, the FDA said Green Innovation GmbH withdrew its food additive petition for animal use. The notice identifies the specific filing as Food Additive Petition number 2401, or FAP 2401, and states the agency assigned the proceeding Docket No. FDA-2021-F-0388. These numbers are the official government identifiers for this specific regulatory request. The notice is the controlling public record for this story, and its conclusion is narrow but concrete: The FDA is no longer acting on FAP 2401 as a route to authorize the requested animal-use additive.
That distinction matters because a food additive petition is the primary legal pathway for a substance intended for use in food-producing animals to gain market access in the United States. The FDA, through its Center for Veterinary Medicine, acts as the gatekeeper. Its authority in this instance, according to the notice, is to administer the petition process under section 409 of the Federal Food, Drug, and Cosmetic Act.
The notice states the withdrawal was made in accordance with Title 21, Section 171.7 of the Code of Federal Regulations, which allows a petitioner to withdraw a request without prejudice. That procedural detail means the company is not legally barred from refiling the petition in the future.
The official filing does not identify the substance, the target animal species, the proposed use level, the consumer food products that might have resulted or the commercial customers involved. The notice only identifies the petitioner as Green Innovation GmbH of Monheim am Rhein, Germany. These omissions are significant. Without those specifics, the paper trail cannot support claims that any particular chicken, dairy, beef, pork, egg or seafood supply chain has gained or lost an input. No approval emerged
The clearest translation is also the least dramatic: This petition did not produce a new authorized animal-use food additive through this docket. A farm cannot rely on this withdrawn petition as evidence that the FDA approved the requested use. A grocery shopper and a restaurant kitchen therefore have no documented new ingredient, label change or menu update to trace to this notice.
This administrative closure is not the same as an agency finding that the additive is unsafe, ineffective, expensive, cheap, helpful or harmful. The Sept. 10 notice published by the FDA records a voluntary withdrawal. It does not publish a safety finding, an enforcement action, a recall, a ban, a price estimate or a health assessment.
The action is distinct from other potential agency outcomes. It is not a "Refuse to File" letter, where the agency determines a petition is too incomplete to even begin a scientific review. Nor is it a formal denial based on safety or efficacy data.
It is simply the formal closure of a docket at the petitioner's request. The regulatory framework The burden of proof rests on the company
Under the Federal Food, Drug, and Cosmetic Act, any substance reasonably expected to become a component of food is a food additive subject to premarket review and approval by the FDA, unless the substance is generally recognized as safe by qualified experts. The law places the burden of proof squarely on the petitioner, in this case Green Innovation GmbH, to demonstrate that the additive is safe for its intended use.
For an additive intended for food-producing animals, that safety demonstration involves multiple steps. The petitioner must show the substance is safe for the target animal. It must also show that any food products derived from treated animals, such as meat, milk or eggs, are safe for human consumption.
This review process requires submitting extensive data on toxicology, residues, manufacturing processes and environmental impact. The petition must also include a proposed analytical method for detecting and measuring the additive in food, ensuring the government can enforce any established safety limits.
The withdrawal of FAP 2401 means the FDA's scientific review of any submitted data has stopped. The agency will not issue a final rule or a finding on the merits of the evidence. The process halted because the applicant stepped away. Without completing this regulatory review, the substance cannot be legally added to animal production systems in the United States. The food chain it touches The farm-input point
Animal-use food additives sit upstream of the plate. Their first potential stop is a farm or animal-production facility, where a legally permitted use could become one element of raising animals that later enter the food system. An additive might be intended to improve growth, prevent disease or enhance the nutritional profile of the final product. As a production input, its cost, availability and legal status are critical business factors for agricultural operators.
From there, any real-world effect would have to travel through processors, distributors, grocery shelves and restaurant kitchens. A change in an input could alter the cost of production, which might eventually influence wholesale and retail prices. It could also result in changes to nutritional characteristics, potentially requiring a label change.
The FDA's Sept. 10 notice proves only that Green Innovation GmbH's petition, FAP 2401, has been withdrawn from that upstream approval route. It does not prove the company sold the additive to farms, that farms were waiting to buy it or that any producer's costs depended on it.
That distinction is not bureaucratic nitpicking. It is the difference between an application disappearing from a government database and an actual shift in the price of a burger, carton of eggs or restaurant entree. The FDA notice documents the administrative event, not a market shift. Plate and bill check
How does this reach dinner plates and restaurant bills? Based on the official record, it does not reach either one. The petition's withdrawal means there is no new animal-use authorization from this proceeding to flow into the farm-input market.
A potential tool for animal agriculture did not receive approval, so it cannot be adopted by farms and cannot affect agricultural operations or costs. The FDA notice supplies no evidence of a current retail product, a restaurant ingredient, a changed label, a disrupted farm purchase or a price fluctuation.
That leaves consumers with a regulatory watch item, not a checkout-line event. If Green Innovation GmbH wants an animal-use additive to enter the regulated market described by this notice, a future filing or a separate authorization record would need to show it. The Sept. 10 action closes Docket No. FDA-2021-F-0388. It does not open a new one. Who gains and who decides The FDA retains gatekeeping power
The Food and Drug Administration, specifically its Center for Veterinary Medicine, is the agency that decides the petition outcome reflected here, per the Sept. 10 Federal Register notice. By publishing the withdrawal, the FDA confirms that FAP 2401 will not remain pending for its decision. The agency gains no commercial benefit stated in the record; it retains its statutory gatekeeping role over the petition pathway as established by Congress in the Federal Food, Drug, and Cosmetic Act.
Green Innovation GmbH is the only named private entity in the supplied official record. The company's legal status as a GmbH, or Gesellschaft mit beschränkter Haftung, indicates it is a private limited liability company organized under German law, as confirmed by its stated location of Monheim am Rhein, Germany. The company gains no product approval from this notice.
What it retains, per the Federal Register notice, is a withdrawn petition. The withdrawal was requested "without prejudice," a legal phrase included in the notice showing the company preserves its right to refile at a later date. The record does not state why the company withdrew, whether it intends to refile, whether it sought the withdrawal for a commercial reason or whether another product pathway is available.
No trade group, farm operator, food manufacturer, restaurant company, retailer, parent company, affiliate, investor or government contractor is identified in the record. Because the additive itself is not named in the notice, it is impossible to identify potential competitors who might gain a market advantage from the withdrawal of a rival's petition. That means there is no documented beneficiary beyond the named petitioner's continued corporate existence, and no basis to assign commercial winners or losers. A direct regulatory relationship
The relationship between the petitioner and the agency follows standard administrative procedures: Green Innovation GmbH was the petitioner for FAP 2401, which is administered by the FDA. The FDA then published the withdrawal of that petition in its Sept. 10 Federal Register notice under Docket No. FDA-2021-F-0388. In the records provided, that is the entire documented point of contact.
There is no supplied lobbying disclosure naming Green Innovation GmbH, no federal contract record from SAM.gov, no grant record from USAspending.gov, no political spending record from the Federal Election Commission and no ownership filing from the Securities and Exchange Commission. There is no documented evidence in this record set that the company paid to influence the FDA, held a contract with the Center for Veterinary Medicine or received federal money tied to this docket. The money trail ends blank No financial disclosures in the record
The FDA Federal Register notice supplies no dollar figure for the petition, no fee amount, no product revenue, no research award, no contract value, no spending estimate and no projected farm-cost effect. It is a procedural notice rather than a financial disclosure. The only numbers it contains are the petition number, FAP 2401, and the docket number, FDA-2021-F-0388, which function as case filing identifiers.
There is no way to document who paid to shape this action, because the federal record does not identify any lobbying client, registrant, payment amount or targeted agency official. To document such an influence, one would need a corresponding filing under the Lobbying Disclosure Act showing payments by Green Innovation GmbH to lobbyists for the purpose of contacting FDA officials regarding this docket. No such record exists in the public filing provided.
The same limit applies to consumer economics. A new additive for animal production can affect costs upstream if it makes animals healthier or more efficient, which might lower costs for farmers. If it were an expensive new technology, it could raise them.
But the FDA's notice does not quantify an input cost, identify a buyer or connect the withdrawn petition to a commodity price or restaurant bill. Claiming grocery bills will rise or fall because of this notice would be inventing details outside the record. No hidden payout in this file
The absence of money records does not prove no money changed hands anywhere in the broader economy. It demonstrates that the FDA notice does not disclose money paid to influence this petition, money awarded to Green Innovation GmbH, or money saved or lost by farms and food businesses.
That is also why this remains a low-risk food-policy event based on the available paper trail. It alters the status of one pending petition, not the legal status of a documented product already moving through grocery or restaurant supply chains. There is no evidence of sunk costs from farmers who purchased a product that was later pulled from the market, because the record shows this product never received market approval in the first place. The timeline is a two-step sequence From request to notice
The timeline established in the Federal Register notice of Sept. 10, 2026, details a short sequence for the withdrawal.
First, at an unspecified earlier date, Green Innovation GmbH submitted FAP 2401 to the FDA. The petition had to exist before it could be withdrawn, though the supplied record does not provide the petition's original filing date.
Second, the Sept. 10 notice states that the action follows a direct request from the petitioner. According to the notice, Green Innovation GmbH submitted a letter to the agency dated Aug. 4, 2026, asking to withdraw the petition.
Third, just over one month later, on Sept. 10, 2026, the FDA published the Federal Register notice titled "Green Innovation GmbH; Withdrawal of Food Additive Petition (Animal Use)," formally closing the matter, as reported by Federal Register.
This short sequence clears up the regulatory record. The action originates with a letter from the company, followed by a procedural notice from the agency. There is no lobbying filing, no contract award and no political contribution record tied to the decision. There is one company letter and one FDA notice recording that its petition is no longer pending. Proven vs. Not Proven The record shows a process, not a verdict
The official records establish that Green Innovation GmbH of Germany submitted Food Additive Petition 2401 for an animal-use substance. They establish that on Aug. 4, 2026, the company asked the FDA to withdraw that petition. They establish that on Sept. 10, 2026, the FDA published a Federal Register notice granting that withdrawal under Docket No. FDA-2021-F-0388.
The petition therefore did not remain on the active route to an FDA decision through this proceeding. The withdrawal was "without prejudice," meaning the company is permitted to refile. These are the documented facts.